Recently, zevaquenabant, a clinical stage hybrid inhibitor of CB1R and iNOS, emerged as a candidate drug for HPSPF, since zevaquenabant treatment attenuated fibrosis progression in bleomycin-induced PF in pale ear mice (HpsPF) (24). Here, CNR1 is linked to pemphigus foliaceus.